Accellacare Archives - Wilmington Health

Primary Hypothyroidism

Medical Condition	Primary Hypothyroidism
Facility/Clinic	Accellacare – 1917 Tradd Ct
Age	18-75 years old
Gender	Male & Female
Description	Armour thyroid treatment for patients taking Levothyroxine for primary hypothyroidism.
Enrollment	Open
Patient Commitment Duration	Up to 90 weeks
Number of visits in study	17-26 visits
Patient Compensation	$25-$225 (varies by visit)

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

HIV Treatment for Newly Diagnosed Adults

Medical Condition	HIV
Facility/Clinic	Accellacare – 2421 Silver Stream Ln
Age	18-65
Gender	Male & Female
Description	A trial to investigate the antiviral effect, safety, tolerability, and pharmacokinetics of orally administered investigational capsid inhibitor monotherapy in HIV-1 infected treatment naive results.
Enrollment	Open
Patient Commitment Duration	2
Number of visits in study	12
Patient Compensation	$89 for all visits except for 1 visit that pays $250

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Type II Diabetes Duodenal Mucosal Resurfacing Study

Medical Condition	Type II Diabetes
Facility/Clinic	Accellacare 1917 Tradd Ct
Age	21-70 years old
Gender	Male & Female
Description	A study to evaluate the efficacy and safety of duodenal mucosal resurfacing using the Revita® system in subjects with type II diabetes on insulin therapy.
Enrollment	Open
Patient Commitment Duration	Minimum of 52 to a maximum of 102 weeks
Number of visits in study	Minimum of 10 to a maximum of 17 visits
Patient Compensation	$100 per on-site visit and $25 for phone calls

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Obstructive Sleep Apnea

Medical Condition	Obstructive Sleep Apnea
Facility/Clinic	Accellacare – 1222 Medical Center Dr
Age	18+
Gender	Male & Female
Description	A study evaluating the efficacy and safety of a once daily oral medication used to treat obstructive sleep apnea.
Enrollment	Open
Patient Commitment Duration	6 months
Number of visits in study	7
Patient Compensation	$25 per phone call visit, $80 per onsite visit, $250 per sleep study (3 total)

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Asthma Sub-Q Biologic

Medical Condition	Asthma
Facility/Clinic	Accellacare – 1222 Medical Center Dr
Age	12+
Gender	Male & Female
Description	A study comparing a new biologic medication to the standard of care, mepolizumab or benralizumab to treat severe asthma.
Enrollment	Open
Patient Commitment Duration	66 weeks
Number of visits in study	18
Patient Compensation	$150/visit

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Idiopathic Pulmonary Fibrosis

Medical Condition	Idiopathic Pulmonary Fibrosis
Facility/Clinic	Accellacare – 1222 Medical Center Dr
Age	40+
Gender	Male & Female
Description	A study to measure the safety and efficacy of two different dosages of study medication versus placebo to treat Idiopathic Pulmonary Fibrosis.
Enrollment	Open
Patient Commitment Duration	minimum of 14 months – up to 4 years
Number of visits in study	14+ visits
Patient Compensation	$100/visit

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Progressive Pulmonary Fibrosis (ILD)

Medical Condition	Progressive Pulmonary Fibrosis (ILD)
Facility/Clinic	Accellacare – 1222 Medical Center Dr
Age	21+
Gender	Male & Female
Description	A study to measure the safety and efficacy of two different dosages of study medication versus placebo to treat Progressive Pulmonary Fibrosis
Enrollment	Open
Patient Commitment Duration	minimum of 14 months – up to 4 years
Number of visits in study	14+ visits
Patient Compensation	$100/visit

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Oral Medication to Treat Chronic Cough

Medical Condition	Chronic Cough
Facility/Clinic	Accellacare – 1222 Medical Center Dr
Age	18-80 years old
Gender	Male & Female
Description	A phase 3, 52-week, randomized, efficacy and safety study with open-label extension of BLU-5937 in adult participants with refractory or unexplained chronic cough.
Enrollment	Open
Patient Commitment Duration	18 months
Number of visits in study	25
Patient Compensation	$50-$100/visit (varies per visit)

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Oral Medication Treating Idiopathic Pulmonary Fibrosis

Medical Condition	Idiopathic Pulmonary Fibrosis (IPF)
Facility/Clinic	Accellacare – 1222 Medical Center Dr
Age	18+
Gender	Male & Female
Description	A phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with idiopathic pulmonary fibrosis (IPF).
Enrollment	Open
Patient Commitment Duration	7 months
Number of visits in study	9
Patient Compensation	$100-$196/visit (varies per visit)

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Inhaler Treating Chronic Obstructive Pulmonary Disease

Medical Condition	Chronic Obstructive Pulmonary Disease (COPD)
Facility/Clinic	Accellacare – 1222 Medical Center Dr
Age	40-80 years old
Gender	Male & Female
Description	A study evaluating the efficacy of bBreztro/Trixeo on cardiopulmonary outcomes in chronic obstructive pulmonary disease.
Enrollment	Open
Patient Commitment Duration	3 months – up to 3 years
Number of visits in study	11+
Patient Compensation	$100/visit

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Biologic Injection Treating Severe Asthma

Medical Condition	Asthma
Facility/Clinic	Accellacare – 1222 Medical Center Dr
Age	12+
Gender	Male & Female
Description	This is a clinical study of a drug called Tezepelumab (TEZSPIRE ®), which is already approved for use in severe asthma. We are looking for adults and adolescents from all ethnic groups to take part. Everyone who joins the PASSAGE study will receive Tezepelumab (TEZSPIRE) at no cast and will get advice and support from the study team.
Enrollment	Open
Patient Commitment Duration	1 year
Number of visits in study	15
Patient Compensation	$75/visit

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.

Progressive Pulmonary Fibrosis Treatment

Medical Condition	Progressive Pulmonary Fibrosis
Facility/Clinic	Accellacare – 1222 Medical Center Dr
Age	18+
Gender	Male & Female
Description	A placebo-controlled study of inhaled pirfenidone in progressive pulmonary fibrosis.
Enrollment	Open
Patient Commitment Duration	1 year
Number of visits in study	12
Patient Compensation	$100 per visit

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-799-5500 between the hours of 8am-5pm for general research questions.